BCL6 is a negative prognostic factor and exhibits pro-oncogenic activity in ovarian cancer.

Abstract

Our study suggests that the inappropriate activation of BCL6 predicts poor prognosis and promotes tumor progression in ovarian carcinoma. Targeting BCL6 could be a novel therapeutic choice for treating ovarian carcinoma patients.